BioCentury
ARTICLE | Financial News

CBT rebrands as Apollomics, raises $100M series B

January 11, 2019 5:54 PM UTC

CBT Pharmaceuticals Inc. has rebranded as Apollomics Inc. (Foster City, Calif.) and raised $100 million in a series B round to advance the development of its immunotherapy and targeted cancer therapy programs globally. The company will also look to increase its pipeline.

CMB International led the round. OrbiMed Asia, which led Apollomics' $9.8 million series A in 2016, also participated in the B round, as did several undisclosed new investors...